How do I buy Immunic, Inc. Common Stock (IMUX) stock?

Buying Immunic, Inc. Common Stock (IMUX) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and verify your identity. Make a deposit. Search for the code "IMUX", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy IMUX by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

What is the minimum investment for IMUX on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in Immunic, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Does Immunic, Inc. Common Stock (IMUX) pay dividends?

At the moment, Immunic, Inc. Common Stock (IMUX) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track IMUX's performance via the price chart in the Gotrade app.

Is buying IMUX on Gotrade safe and legal?

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

What are the market hours to buy IMUX?

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too. The market is closed on US public holidays. The Gotrade app shows whether the market is open.

How do I tell if IMUX is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Immunic, Inc. Common Stock (IMUX) Stock Price: Nov 11 Close $8.12

News tone: automated (AI) classification of the article's content, not a price prediction.

About Immunic, Inc. Common Stock

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

SectorHealthcare

IndustryBiotechnology

Employees100

CEOMr. Erik Lundgren

IPO DateApr 17, 2014

HeadquartersNew York, NY

Key Executives

Name	Title	Year Born
Mr. Erik Lundgren	CEO & Director	1978
Mr. Jason Tardio M.B.A.	COO & President	1977
Mr. Glenn Whaley CPA	Chief Financial Officer	1968
Dr. Hella Kohlhof	Co-Founder & Chief Scientific Officer	1973
Ms. Jessica Breu	Vice President of Investor Relations & Communications	—
Mr. Inderpal Singh	General Counsel	1966
Mr. Patrick Walsh	Chief Business Officer	1983
Mr. Werner Gladdines	Chief Development Officer	1979
Dr. Michael A. Panzara M.D., M.P.H.	Chief Medical Officer	1967
Mr. Chitrang Davé	Chief Data & Digital Officer	—

Fundamentals

Valuation

Price-to-book value0.86

Profitability

Return on Equity-158.00%

Return on Assets-108.00%

EBITDA$-110.67M

Trading

Average volume306,852

Source: third-party data provider, as of November 13, 2026

Technical indicators

RSI 14: 50.64
MACD 12/26/9: -0.26
EMA 9 of MACD: -0.47
MACD histogram: 0.21
SMA 50: $8.93; Price below SMA 50
EMA 50: $9.11; Price below EMA 50
SMA 200: $11.55; Price below SMA 200
EMA 200: $10.06; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst views

3 analyst ratings

Third-party analyst opinion, not a recommendation from Gotrade.

Analyst consensus:Buy

100% Buy

0% Hold

0% Sell

Analyst price target

Low: $22.00
Average: $33.50
High: $45.00

Wedbush

Martin Fan

Buy

Target price

$45.00

HC Wainwright & Co.

Matthew Caufield

Buy

Target price

$22.00

Cantor Fitzgerald

Yanni Souroutzidis

Buy

Target price

-

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2026				+6.8	+55.0	+1.6	-5.7	+12.1	-36.2	-13.1	+10.6

Corporate actions

Upcoming

No upcoming corporate actions for IMUX

Past

Reverse stock split

Split date27 Apr 2026

Ratio10 : 1

Compare stocks

IMUX

Buy IMUX

Market cap

$110.79M

-

Price / Earnings ratio

-1.00

-

Price / Sales ratio

-

Dividend yield

0.00%

-

Average volume

306,852

-

Earnings per share

$-3.88

-

Immunic, Inc. Common Stock (IMUX) Stock

Key stats

Compare with IMUX

Recent news

New Strong Buy Stocks for October 22nd

New Strong Buy Stocks for October 22nd

Immunic adds new Chief People Officer ahead of Phase 3 readout

Immunic adds new Chief People Officer ahead of Phase 3 readout

Immunic to host virtual relapsing MS R&D Day on September 9

Immunic to host virtual relapsing MS R&D Day on September 9

Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect?

Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect?

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

New Strong Buy Stocks for October 22nd

New Strong Buy Stocks for October 22nd

Immunic adds new Chief People Officer ahead of Phase 3 readout

Immunic adds new Chief People Officer ahead of Phase 3 readout

Immunic to host virtual relapsing MS R&D Day on September 9

Immunic to host virtual relapsing MS R&D Day on September 9

Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect?

Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect?

Immunic advances MS drug toward key Phase 3 data, expects results by year-end

Immunic advances MS drug toward key Phase 3 data, expects results by year-end

Immunic presents new vidofludimus calcium data at multiple sclerosis conference

Immunic presents new vidofludimus calcium data at multiple sclerosis conference

Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials

Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials

Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout

Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout

Immunic advances Phase 3 MS program, eyes topline data by year-end

Immunic advances Phase 3 MS program, eyes topline data by year-end

Immunic appoints Michael Panzara as CMO ahead of pivotal MS drug readout

Immunic appoints Michael Panzara as CMO ahead of pivotal MS drug readout

About Immunic, Inc. Common Stock

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Corporate actions

Upcoming

Past

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade